These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
38. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587 [TBL] [Abstract][Full Text] [Related]
39. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613 [TBL] [Abstract][Full Text] [Related]
40. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]